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Abstract
Mutations in PANK2 lead to neurodegeneration with brain iron accumulation. PANK2 has a
role in the biosynthesis of coenzyme A (CoA) from dietary vitamin B5, but the neuropatho-
logical mechanism and reasons for iron accumulation remain unknown. In this study, atypi-
cal patient-derived fibroblasts were reprogrammed into induced pluripotent stem cells
(iPSCs) and subsequently differentiated into cortical neuronal cells for studying disease
mechanisms in human neurons. We observed no changes in PANK2 expression between
control and patient cells, but a reduction in protein levels was apparent in patient cells. CoA
homeostasis and cellular iron handling were normal, mitochondrial function was affected;
displaying activated NADH-related and inhibited FADH-related respiration, resulting in
increased mitochondrial membrane potential. This led to increased reactive oxygen species
generation and lipid peroxidation in patient-derived neurons. These data suggest that mito-
chondrial deficiency is an early feature of the disease process and can be explained by
altered NADH/FADH substrate supply to oxidative phosphorylation. Intriguingly, iron
chelation appeared to exacerbate the mitochondrial phenotype in both control and patient
neuronal cells. This raises caution for the use iron chelation therapy in general when iron
accumulation is absent.
Introduction
Neurodegeneration with brain iron accumulation (NBIA) disorders are a set of clinically anal-
ogous neurological diseases characterised by neuropathology of the basal ganglia coinciding
with iron deposition [1]. Patients display pyramidal and extrapyramidal movement disruption
as well as cognitive decline. Pathological examination highlights either axonal swellings with
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ubiquitinated aggregates, tau tangles or Lewy bodies depending on the NBIA subtype. Muta-
tions in 12 genes have been shown to cause NBIA and each protein has a seemingly disparate
cellular function [2]. These functions include iron metabolism, mitochondrial metabolism,
lipid homeostasis and autophagy.
The most common NBIA subtype is pantothenate kinase-associated neurodegeneration
(PKAN), caused by recessive mutations in the PANK2 gene [3]. This accounts for 35–50% of
all NBIA cases [4,5]. Pantothenate kinase (PANK) catalyses the first step of coenzyme A (CoA)
biosynthesis from dietary vitamin B5. CoA has critical roles in multiple mitochondrial meta-
bolic pathways, including the TCA cycle, β-oxidation and fatty acid synthesis. There are four
human PANK isoforms; PANK1 and PANK3 are cytosolic, whereas PANK2 is localised to the
mitochondria [6]. There is still some contention over the localisation of mouse Pank2 between
the mitochondrial membranes [7] and the cytosol [6,8]. PANK4 is an isoform presumed to
lack catalytic activity [9]. CoA is present in the mitochondrial matrix at 1000-fold higher levels
than in the cytosol [10] and PANK2 is the major active PANK isoform in the human brain.
Despite rodent brain tissue being less enriched for Pank2 than human brain, its central role is
demonstrated as Pank2 knockout mice have 60% reduced total PANK activity in neural tissue
[11]. These data support a primary role for PANK2 and CoA in neuronal mitochondria. How-
ever, mitochondrial CoA is yet to be measured in patient-derived or mouse model brain tissue.
The mechanism by which PANK2 mutations lead to neurodegeneration is not known but
several animal models have been generated to facilitate investigation of disease mechanisms.
Drosophila have one Pank orthologue and deletion partially recapitulates some of the move-
ment phenotypes and reduced lifespan observed in PKAN [12,13]. Addition of human mito-
chondrial PANK2 is able to rescue this phenotype [13]. Interestingly, while Drosophila
cytosolic Pank isoforms are not able to rescue knockout fly phenotypes, addition of the human
cytosolic isoforms provide a partial rescue. Pank2 knockout mice also show a similar pheno-
type, but only when metabolically stressed with a ketogenic diet [14]. These animal models fail
to display iron accumulation. Patient fibroblasts have been shown to display defective iron
handling, increased reactive oxygen species damage (ROS) and mitochondrial physiological
deficits [15]–findings that were replicated in human neurons for the first time after direct
reprogramming from patient fibroblasts [16] and subsequently reinforced in iPSC-derived
neurons [17].
PKAN patients display iron accumulation in the globus pallidus and have cellular pathol-
ogy, namely axonal swellings and gliosis, affecting the cortex as well as the neurons of the glo-
bus pallidus [18,19]. Despite being an essential element of cell survival, it is unclear whether
iron accumulation is causative or consequential to neurodegeneration. Many cellular enzymes
make use of heme iron for normal folding and function as well as iron-sulphur clusters for
enzymatic function; notable examples are the complexes of the electron transport chain of oxi-
dative phosphorylation. Deregulated iron can be potentially harmful to the cell as, depending
on its oxidative state, it can lead to free radical formation via the Fenton reaction. Therefore,
tight cellular mechanisms for import, storage and export of iron from the cell exist [20]. Neu-
ronal iron is predominantly imported via endocytosis of the Transferrin Receptor (TfR) and
either stored intracellularly through complexes such as Ferritin, consisting of both heavy
(FTH) and light (FTL) chains, or utilized immediately by the cell for normal function. For its
use in aerobic respiration, iron is imported into the mitochondria via mitoferrin transporters
(MFRN1/2) and mitochondrial specific ferritin (MTFT) stores mitochondrial iron until it is
required or when in excess. Iron is exported from neurons via Ferroportin (FPN), which
requires cell surface stabilization through binding to β-amyloid precursor protein [21,22]. Iron
within a healthy cell is predominantly contained within mitochondria and lysosomes [23] and
upon entering the mitochondria it is thought to accumulate as no mitochondrial iron exporter
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has been described thus far. This has led to the suggestion that mitophagy may be a mechanism
for liberating iron from mitochondrial stores [24].
The present study sets out to investigate the consequences of PANK2 mutations on iPSC-
derived cortical neuronal cells in culture. Fibroblasts from three atypical PKAN patients were
reprogrammed to iPSCs and, along with three control pluripotent stem cell (PSC) lines, differ-
entiated into cortical neuronal cells using a highly efficient differentiation paradigm. Mito-
chondrial dysfunction was observed, namely altered NADH and FADH supply to oxidative
phosphorylation as well as increased reactive oxygen species (ROS) production and oxidative
damage. Changes to iron and CoA metabolism were not witnessed. Additionally, it was shown
that iron chelation led to increased oxidative damage in patient and control neuronal cells.
These findings enable analysis of early pathological events in PKAN without the context of
aging and complex late-stage disease.
Materials and methods
Cell culture and reprogramming of fibroblasts
All culture reagents were purchased from Thermo Fisher unless otherwise stated. Patient biop-
sies were taken using a skin punch under informed consent (ethical approval from the NHNN
and IoN joint research ethics committee, study number 10/H0721/87). Fibroblasts were cul-
tured as previously described [25]. Briefly, 5mm biopsies were taken with a skin punch and
then allowed to expand in DMEM supplemented with 10% FBS. Fibroblasts were passaged
using 0.05% trypsin/EDTA.
Fibroblasts were reprogrammed using the episomal plasmids as described by Okita et. al.
[26]. The episomal plasmids were obtained from Addgene (plasmids #27077, #27078 and
#27080) and fibroblasts were nucleofected using the Lonza P2 nucleofection kit (Amaxa).
Nucleofected cells were changed to iPSC culture media after 7 days and colonies were manu-
ally picked after they appeared around 30 days post nucleofection. iPSCs and hESCs were
maintained in Essential 8 media on Geltrex coated plates. Cells were routinely passaged using
0.5 mM EDTA. Karyotype counts and G banding analysis was performed by Cell Guidance
Systems (Cambridge, UK).
At least two clonal iPSC lines from each patient were taken forward for experimentation
and compared to two control iPSC lines and one hESC line; termed Control 1, Control 2 and
hESC Control respectively. The hESC line Shef6 was obtained from the UK Stem Cell Bank,
Control iPSC line 1 was generated from a neurologically normal individual in the lab of Dr
Tilo Kunath and Control iPSC line 2 was obtained from the Coriell repository.
Stem cells were differentiated to cortical neuronal cells using the protocol described by Shi
et. al. [27]. Briefly, cells were subjected to 10 days dual SMAD inhibition using 1 μM dorso-
morphin (Tocris) and 10 μM SB431542 (Tocris), followed by extended neurogenesis in N2B27
media containing retinoids. The final time point for all experiments was taken as 100 days post
neural induction.
Immunocytochemistry
Cells were fixed in 4% PFA, washed three times in PBS with 0.3% Triton X-100 (PBST) to per-
meabilize the cells and blocked in 3% BSA. Primary antibodies (Table 1) were incubated over-
night at 4˚C in blocking solution. Cells were then washed three times in PBST and secondary
antibodies (Alexa Fluor, Thermo Fisher) were added for 1 hour at room temperature in the
dark in blocking solution. Finally, cells were washed once with PBST containing 1 μM DAPI
and then twice in PBST before being fixed and mounted. Images were taken on a Zeiss LSM
microscope or a Zen confocal microscope. Counting data was taken from 5 images per
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replicate; areas were randomly selected in the DAPI channel and automated counting was per-
formed using the ITCN nuclear counting plugin for Image J, using the same threshold setting
throughout.
qPCR
RNA was isolated from samples using Trizol reagent and purification was performed following
the manufacturers’ instructions (Thermo Fisher). Reverse transcription was performed on
2 μg of RNA using Superscript reverse transcriptase III and random hexamer primers. Power
Sybr Green mastermix (Thermo) was used for the qPCR reaction on the Agilent MX3000P
qPCR system with annealing temperatures of 60˚C for all primers used (Table 2). All results
are relative to three housekeeping genes GAPDH, Cyclophilin and β-actin.
Western blot analysis
Samples were treated with 50 μM FAC for 18 hours in normal cell culture media. Samples
were lysed in RIPA buffer containing 10 mM Tris pH 8, 140 mM NaCl, 1 mM EDTA, 0.5 mM
EGTA, 1% Triton X-100 0.1% sodium deoxycholate, 0.1% SDS plus protease and phosphatase
inhibitors (Roche), for one hour on an orbital shaker at 4˚C, followed by centrifugation at
10,000 g for 15 minutes at 4˚C. Protein concentrations were measured using the BSA assay
(Biorad) and samples were separated on a NuPage 10% SDS polyacrylamide gel (Novex) before
being transferred onto a nitrocellulose membrane for western blotting. Membranes were
blocked in 3% milk in PBS containing 0.1% Tween 20. Primary antibodies were added to the
membranes in blocking solution overnight at 4˚C. Blots were then washed three times before
secondary antibodies were added in blocking solution for one hour. After final washes, images
were captured and densitometry analysis performed on the Li-Cor Odyssey imaging system
(Li-Cor).
HPLC
CoA species were extracted from cells with ice-cold perchloric acid (PCA, 3.5%). After centri-
fugation at 21,000 g for 5 min at 4˚C, the supernatant, containing CoASH and short-chain
CoA esters, was collected and 1 M triethanolamine (TEA) was added to a final concentration
of 100 mM. The pH was adjusted to pH 6 with 5 M K2CO3 and potassium perchlorate pellet
was removed by centrifugation at 21,000 g for 3 minutes at 4˚C. For the quantification of the
Table 1. Antibodies used for ICC and Western blotting.
Antibody Name Source Dilution Species
OCT4 Santa Cruz sc-5297 1:500 gt
SSEA4 BioLegend MC-813-70 1:200 m
OTX2 Millipore AB9566 1:400 rb
Ki67 BD 550609 1:500 m
TUJ1 BioLegend 801201/802001 1:1000 m/rb
TBR1 Abcam ab31940 1:500 rb
SATB2 Abcam ab51502 1:100 m
CTIP Abcam ab18465 1:500 rat
PANK2 (3H9) Abcam ab119070 1:1000 m
TfR Invitrogen 13–6800 1:500 m
FTH1 NEB 3998 1:500 rb
GAPDH Ambion AM4300 1:5000 m
https://doi.org/10.1371/journal.pone.0184104.t001
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total level of acid-soluble CoA esters (combined level of unesterified CoA and short chain
CoA), 5 M KOH and 100 mM tris (2-carboxyethyl) phosphine were added to neutralized PCA
extracts to final concentrations of 0.5 M and 10 mM, respectively. KOH hydrolyses all PCA-
soluble esters into unesterified CoA which were then measured by HPLC. After incubation at
25˚ C for 5 minutes, the pH was adjusted to pH 6 with 5% PCA. CoASH and short-chain CoA
esters were measured by HPLC as previously described [28] except EDTA was omitted from
the injection mixture. For the quantification of total long-chain acyl CoAs, the PCA pellets
were solubilised in 89 mM TEA, 0.44 mM KOH and 11.1 mM DTT by gentle sonication to
hydrolyse long-chain CoA esters to unesterified CoA. After incubation for 5 min at 25˚ C, pro-
teins were precipitated by PCA and pelleted by centrifugation at 21,000 g for 10 min at 4˚C.
The supernatant was collected and the pH was adjusted to 6–7 with 0.5 M K2CO3 and centri-
fuged again at 21,000 g for 3 min at 4˚C. The supernatant was collected and CoA was measure-
ment by the CoA recycling assay [29] adapted to a plate reader format.
Mass spectrometry
The UPLC-MS/MS instrument consisted of a Waters ACQUITY UPLC system coupled to a
Xevo TQ-S triple quadrupole mass spectrometer with an electrospray ionization source. The
mass spectrometer was operated in negative ion mode and data were acquired using MassLynx
V4.1 software. Chromatographic separations were achieved using a Waters CORTECS C18 col-
umn (1.6 μm, 2.1 x 50 mm), with a CORTECS C18 VanGuard pre-column (1.6 μm), which was
maintained at 40˚C. Binary gradient profiles were developed using water with 0.01% formic
acid (A) and methanol (B) (HPLC grade, Merck) at a flow rate of 700 μL/min. Separations
were conducted under the following chromatographic conditions: 100% solvent A for 1 min,
decreased to 10% over 1 min, maintained for 1 min at 10% before being increased to 100%
over 0.1 min. Column equilibration time was 0.9 min, with a total run time of 4 min. The injec-
tion volume was 10 μL. Mass spectrometric conditions were as follows: capillary voltage 2.5
kV, cone voltage 60 V, source temperature 150˚C, desolvation temperature 600˚C, cone gas
flow 150 L/h, desolvation gas flow 800 L/h, collision gas flow 0.25 L/h and nebulizer gas flow 7
bar. Dwell time was set at 8 msec for each analyte. The quantitation of vitamin B5 and
Table 2. Primers used for qPCR.
Gene Forward Primer Reverse Primer Product
GAPDH atgacatcaagaaggtggtg cataccaggaaatgagcttg 177bp
CYCLOPHILIN ggcaaatgctggaccaaacac ttcctggacccaaaacgctc 147bp
b-ACTIN tcaccaccacggccgagcg tctccttctgcatcctgtcg 351bp
OCT4 Ttctggcgccggttacagaacca gacaacaatgaaaatcttcaggaga 218bp
SOX2 catggcaatcaaaatgtcca tttcacgtttgcaactgtcc 119bp
NANOG Gcttgccttgctttgaagca ttcttgactgggaccttgtc 256bp
VIMENTIN gtacgtcagcaatatgaaag agtgtcttggtagttagcag 270bp
S100A4 Ttctttcttggtttgatcc ttagttctgacttgttgagc 211bp
TfR gacgcgctagtgttcttc actgttatcgccatctactt 136bp
FPN tctctctacttggggagat tcagaagctcatgtttatgta 266bp
FTH cagaactaccaccaggact agtatttggcaaagttcttc 136bp
FTL tctcaagcacgactaagag gcagaagccctattacttt 74bp
MFRN1 aatcgagctccatactaaag gtcccctcctctctctaa 164bp
MFRN2 gtgatgtaccccatcgac cgttcttataatcctccaga 108bp
FTMT agtgtgctctactcttggaa gtcacctttatctgaggcta 77bp
PANK2 tcagtcggattcaatgga aagcagaggatacggatt 108bp
https://doi.org/10.1371/journal.pone.0184104.t002
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isotopically-labelled vitamin B5 (Sigma) was then performed using the multiple reaction moni-
toring (MRM) method described in Table 3. It is important to note for isotopically labeled
pantothenate, treatment was performed in media deficient of pantothenate: HBSS media sup-
plemented with N2 and B27 supplements, NEAA and L-glutamine as the above media recipes.
Sample preparation. Cell pellets were reconstituted in 20 μL of buffer (pH 7.8), consisting
of 100 mM Tris base, 6 M urea, 2 M thiourea and 2% ASB-14 (adjusted to pH 7.8 with HCl).
Samples were shaken for 30 minutes (1000 rpm; 37˚C) before being diluted 1:100 with water
and analyzed via UPLC-MS/MS.
Inductively-coupled-plasma mass spectroscopy (ICP-MS)
Cellular iron content was analyzed by ICP-MS using the protocol previously reported [21].
Briefly, 150 μg of total protein as measured by Bradford protein assay, was lyophilized before
resuspension in 100 μl nitric acid (69% v/v; ultraclean grade, Aristar) overnight at room tem-
perature (RT). Samples were then heated for 1 hour at 90˚C, before the addition of an equiva-
lent volume of hydrogen peroxide (30%, Merck). Sample was incubated for 15 min at RT
before a further 30 min at 70˚C. To evaluate metal content against calibration standards
(#IMS-102; Ultra Scientific) samples were diluted in double-distilled water until within quanti-
fiable parameters using a NexION 350X inductively coupled plasma mass spectrometer (Perki-
nElmer, Waltham, MA, USA). Each sample was measured in triplicate and normalized to total
protein concentration.
Live cell imaging
For live cell imaging iPSC cells were incubated with 25 nM TMRM (tetramethylrhodamine,
methyl ester; a cell permeant, cationic, red-orange fluorescent dye sensitive probe for mito-
chondrial membrane potential and used in the redistribution mode) for 40 minutes in a
HEPES-buffered salt solution (HBSS) composed of (mM): 156 NaCl, 3 KCl, 2 MgSO4, 1.25
KH2PO4, 2 CaCl2, 10 glucose and 10 HEPES; pH 7.35. Images were obtained using a Zeiss 710
Laser Scanning Microscope (CLSM) with an integrated Meta detection system and a 40x oil-
immersion objective. Illumination intensity was kept at the minimum of laser output and the
pinhole was set to give an optical slice of *1 μm. TMRM was excited using the 560 nm laser
line and fluorescence measured above 580 nm. Calcein-AM based cell area measurements
were used for normalization. The NADH autofluorescence was measured with excitation at
405 nm and emission at 440–480 nm. FAD autofluorescence was determined using 458 nm
Argon laser line and fluorescence was measured from 505 to 550 nm.
FAD and NADH redox indexes and mitochondrial pools were estimated by sequentially
applying 1 μM of the mitochondrial uncoupler FCCP (carbonyl cyanide p-trifluoromethoxy-
phenylhydrazone), followed by 1 mM of the complex IV inhibitor sodium cyanide [30]. Lipid
peroxidation experiments were performed using, C11-BODIPY (581/591, 2 μM, Molecular
Probes) was excited at the 488 and 565 nm laser lines and fluorescence measured from 505 to
550 nm and above 580 nm (40x objective). GSH levels were assessed using monochlorbimane,
Table 3. MRM conditions for the analysis of vitamin B5 and isotopically-labelled vitamin B5 including retention times, collision energy, precursor
ions and their respective quantifier and qualifier ions.
Compound Retention time
(min)
Precursor ion(m/
z)
Quantifier ion
(m/z)
Collision energy
quantifier (V)
Qualifier ion(m/
z)
Collision energyqualifier
(V)
vitamin B5 1.56 218.2 88.0 10 146.0 12
13C6,15N2 vitamin
B5
1.56 222.1 92.0 10 147.0 12
Mitochondrial dysfunction in PKAN iPSC-neurons
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MCB (Molecular Probes, Invitrogen) fluorescence with excitation at 351 nm and emission at
435–485 nm. Data were acquired and analyzed using ZEN2009 software. Superoxide genera-
tion was measured with Dihydroethidium (HEt; 2 μM, Invitrogen). Fluorescent images were
acquired with a frame interval of 10 s. Data were analyzed using software from Andor IQ (Bel-
fast, UK). Statistical analysis and data analysis were performed using Origin 9 (Microcal Soft-
ware Inc., Northampton, MA, USA) software. Results are expressed as means ± standard error
of the mean (SEM).
Sanger sequencing
gDNA was extracted from iPS cells and differentiated neuronal cells from all utilised patients
and control clones using a standardized phenol extraction.
Primers and touch-down PCR programmes as available in Table 4 were utilised to Sanger
sequence the specified mutations within the PANK2 gene as given in Table 5 for the respective
disease and control clones to confirm their presence/absence.
Statistical analysis
Data represent three control PSCs and at least two clones from three unrelated PKAN patients.
Number of independent inductions is depicted in histograms. Where appropriate, statistical
significance was calculated using the Student’s t test or ANOVA, as stated. Histograms repre-
sent mean values and error bars represent standard error of the mean. p<0.05, p<0.01,
p<0.001.
Results
Generation of patient-derived iPSCs and cortical neuronal cells
iPSC lines from three NBIA patients with confirmed PANK2 mutations were generated to
study the mutation effect in human neurons in vitro (Table 5). These patients each have com-
pound mutations leading to atypical PKAN with later disease onset and less severe progression
than classical PKAN (Table 5). Clinically, these patients display iron accumulation evident by
T2 MRI and a generalised dystonia phenotype.
Fibroblasts from the 3 patients were reprogrammed to iPSCs using the non-integrating
episomal reprogramming method [26]. At least two iPSC clones from each patient were picked
and expanded for further characterisation, alongside two control iPSC lines and one control
hESC line. To confirm pluripotency in the newly derived iPSC lines, expression of the pluripo-
tency markers OCT4 and SSEA4 were immunocytochemically identified (Fig 1A). PANK2
Table 4. Primer sequences, amplicon size and TD-PCR programmes for gDNA Sanger sequencing of PANK2-mutations. Detailed Sanger sequenc-
ing protocol and cycling conditions upon request.
Patient
Number
Mutation Primer F Seq Primer R Seq amplicon
size
PCR
programme
1 R481Lfs*Q PANK2_x5_F-iPS tgttgggctttgttgctgtt PANK2_x5_R-iPS aacaaaccccaccccaaatg 297 TD65_55
1 G521R PANK2_x6_F-iPS catggtgctgtatttggggt PANK2_x6_R-iPS ccatttcacctccaccctct 302 TD65_55
2 IVS4–1
G>T = splice
acceptor just
before exon 5
PANK2_x5spli_F-
iPS
tggagggctctgtttgaagt PANK2_x5spli_R-
iPS
tggccaggtcctctttactg 242 TD65_55
2 M437T PANK2_x4_F agggaggaggtgttagcatg PANK2_x4_R agggaggaggtgttagcatg 458 TD65_55
3 R278L PANK2_x2_F-iPS tcggtggaactctggtcaag PANK2_x2_R-iPS atttgtacgctccacctcca 309 TD65_55
3 L564P PANK2_x7_F-iPS gggtgctcaggaaatgggta PANK2_x7_R-iPS aaatcctcacactgcctgga 416 TD65_55
https://doi.org/10.1371/journal.pone.0184104.t004
Mitochondrial dysfunction in PKAN iPSC-neurons
PLOS ONE | https://doi.org/10.1371/journal.pone.0184104 September 1, 2017 7 / 22
iPSCs displayed similar expression of these pluripotency markers and characteristic colony
morphology to control lines. qPCR analysis also showed that the gene expression of the core
pluripotency markers OCT4,NANOG and SOX2 was comparable to hESCs in contrast to
nascent fibroblasts (Fig 1B) and that the newly formed iPSCs faithfully silenced fibroblast
markers S100A4 and VIMENTIN (Fig 1C). The genomic integrity of the newly formed lines
was confirmed by karyotype stability and G-band analysis (S1 Fig) and all disease lines were
confirmed to carry the compound heterozygous mutations by Sanger sequencing (S1 Fig), as
specified in Table 4. Absence of these mutations was confirmed in control PSC lines.
To generate neurons, we subjected the iPSCs to a cortical differentiation protocol due to
the very high efficiency of differentiation (>95%) [27,31]. All lines tested from the patient-
derived iPSCs were able to faithfully generate forebrain patterned neural precursor cells, ex-
pressing the telencephalic marker OTX2 (Fig 1A). After 100 days of neurogenesis, control and
patient-derived PSCs generated deep layer (TBR1-positive), upper layer (SATB2-positive) and
middle layer (CTIP2-positive) cortical neuronal cells (Fig 1A). The ability of lines to undergo
cortical neurogenesis showed some variability but was comparable between all patient lines
(Fig 1D), consistent with a non-developmental disease. Sanger sequencing was performed on
genomic DNA from terminally differentiated cells and all patient-derived heterozygous muta-
tions were confirmed (S1 Fig). Western blot analysis demonstrated a reduction of mature
PANK2 protein in patient-derived neuronal cultures in comparison to control cell cultures,
(patient 1 32.8±4.1%; patient 2 36.5±4.5%; patient 3 30.2±2.1%), despite only one patient dis-
playing a premature stop codon mutation (Table 5).
CoA homeostasis in patient-derived neuronal cells is comparable to
control
Only a subset of mutations in PANK2 that lead to PKAN reduce enzyme activity and affect
protein folding [32,33]. Indeed, changes in CoA levels in human cell lines or brain tissue have
yet to be demonstrated [2]. Therefore, absolute levels of CoA and acetyl-CoA were investigated
in the cultures via HPLC.
Primary analysis of the free CoA to acetyl-CoA ratio in iPSC cultures and differentiated
cells indicated an undefined switch in the metabolic states between the two cell types, seen via
a relative decrease in free CoA and an increase in acetyl-CoA levels in neuronal cells. This
ratio change between iPSCs and neurons was independent of PANK2 mutation (S2 Fig).
No change in short chain CoA species (free CoA (CoASH), acetyl-CoA and short-chain
CoA esters) was observed by HPLC (Fig 2A and 2B). As it has been previously reported that
PANK2 mutations could lead to the disruption of β-oxidation of fatty acids [33], long chain
Table 5. Overview of clinical and genetic features of atypical PKAN cases. PANK2 transcript: ENST00000316562.
Patient Mutation Gender Age of
Onset
[y]
Age at
biopsy
(y)
Current
Age [y]
Predominant
Phenotype
MRI FH Clinical
diagnosis
1 R481Lfs*Q + G521R M 12 41 Deceased
at age 43
Generalised
dystonia
Iron deposition on basal
ganglia.
Negative PKAN
2 IVS4–1 G>T = splice
acceptor site just before
exon 5 + M437T
F 15 39 42 Anarthria,
dystonia
Marked hypodensity
bilaterally and
symmetrically within the
globi pallidi.
Negative PKAN
3 R278L + L564P M 6 41 45 Generalised
dystonia
Eye of the tiger in the
globi pallidi.
Negative PKAN
PKAN—pantothenate kinase associated neurodegeneration. MRI—magnetic resonance imaging, FH—family history, M—male, F—female, y—year.
https://doi.org/10.1371/journal.pone.0184104.t005
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Fig 1. Characterization of PANK2 iPSCs and differentiated neuronal cultures. A) Immunocytochemistry on
three control lines and newly generated iPSC lines from three PANK2 mutation carriers to confirm pluripotency
in iPSC cultures and successful neuronal differentiation. i) Pluripotency of iPSC used in this study was
confirmed by positive immunofluorescence for OCT4 and SSEA4. ii) At day 25 of neuronal induction, neuronal
precursors were present in all cultures with rosette morphology and showed positive immunofluorescence for
the forebrain marker OTX2 and proliferative marker Ki67. iii) After 100 days of differentiation, cultures
expressed the pan-neuronal marker β-III-tubulin as well as deep (TBR1-positive), middle (CTIP2-positive) and
upper (SATB2-positive) layer cortical markers. iv) Neuron-like morphology was evident at higher magnification.
B) Further confirmation of pluripotency in nascent iPSC lines was obtained by qPCR analysis to show
expression of the pluripotency markers OCT4, NANOG and SOX2. Expression levels were normalized to those
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CoA derivatives were also evaluated. While some variability arose between cell lines (Fig 2C),
no overall significant difference was observed between control and mutant lines (Fig 2D).
Together, these data signify a comparable steady state of total CoA levels in the patient-derived
neuronal cells to control cultures.
To infer changes of synthesis and breakdown of CoA in patient-derived neuronal cultures,
stable isotope labelled vitamin B5 was used to measure neuronal uptake and handling (Fig 2E).
Cells treated with labelled vitamin B5 (pantothenate) for up to 24 hours displayed a similar
rate of uptake between control and patient-derived neuronal cultures (Fig 2E). No change also
inferred that the cellular lifetime of vitamin B5 was unaffected by the presence of the PANK2
mutation, shown via similar homeostasis of the labelled pantothenate.
Patient-derived neuronal cells exhibit dysfunctional mitochondrial
respiration
In order to test whether the mutations in PANK2 affect the mitochondrial health in our iPSC-
derived neuronal cells, mitochondrial membrane integrity and live cell imaging experiments
were performed.
Mitochondrial membrane potential (Δψm), is an indicator of mitochondrial function, and
was assessed using TMRM fluorescence (Fig 3A and 3B). The presence of the PANK2 mutation
increased Δψm in both iPSC (pooled controls: 470.3±72.2, n = 48 versus pooled patients:
1207.0±95.3, n = 72. p<0.0001) and neuronal cells (pooled controls: 1254.3±67.7, n = 48;
versus pooled patients: 1685.6±135.1, n = 106; p = 0.005, Fig 3Aii). Changes in mitochondrial
membrane potential have been reported in other PKAN models [7,16], albeit with opposing
results. Here, altered maintenance of Δψm is likely to represent a compensatory mechanism to
mitochondrial deficits. Some variability between cell lines was apparent, as demonstrated by
patient 2 and 3 derived cells displaying significantly higher Δψm compared with controls,
whereas patient 1 derived cells consistently demonstrated Δψm similar to control lines (Fig
3A). Due to this variability, data for individual cell lines is presented, and significant compari-
sons are depicted by the pooled data (Fig 3Aii).
The known association of PKAN pathology with brain iron accumulation led us to examine
whether iron was involved in changes to the mitochondrial membrane potential observed in
patient cells (Fig 3C and 3D). Pre-treatment with the iron chelator deferoxamine (DFO) at
50 μM for 30 minutes increased neuronal Δψm (control 1: 1317.7±65.8 to 2023.8±104.3,
n = 48; control 2: 1025.7±62.8 to 3741.2±149.3, n = 49; patient 1: 1987.3±96.2 to 3999.4±270.7,
n = 33; patient 2: 1864.0±256.1 to 2272.3±238.3, n = 49; patient 3: 2272.3±238.3 to 3989.1
±51.6, n = 49. p<0.001) representing a further increase in membrane potential above non-
treated PKAN-associated levels as a result of iron chelation (Fig 3C and 3D).
The basis for differences in Δψm maintenance was further investigated by exposing the cells
to known specific inhibitors of the electron transport chain complexes (Fig 3E). A comparable
in human embryonic stem cells. Fibroblasts were included as a negative control. C) Downregulation of fibroblast
enriched gene expression, S100A4 and VIM, was assessed using qPCR. Normalization to untransfected
fibroblasts demonstrated low expression in newly derived iPSCs similar to embryonic stem cells. D)
Quantification of the relative proportions of TBR1, CTIP2 and SATB2 positive cells relative to total cell numbers
in differentiated cultures. Individual data represent 2 iPSC clones from patient 1, 3 clones from patient 2 and 1
clone from patient 3. E) Representative western blot analysis of PANK2 protein levels in whole cell lysates from
control and patient neuronal cultures at day 100 of differentiation. PANK2 was observed at the predicted
molecular weight of 48kDa. Actin was used as a loading control. F) Quantification of western blot data from
three independent inductions showed consistently lower levels of PANK2 in patient neuronal cells. Scale bar
represents 100 μm for all images, and 20 μm for Aiv. Numbers in histogram bars represent experimental
replicates.
https://doi.org/10.1371/journal.pone.0184104.g001
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decrease (~70% of basal levels) in control and PKAN neuronal cells of TMRM signal after oli-
gomycin treatment (complex V inhibitor), suggested complex V in these cells was working in
reverse as an ATPase to maintain mitochondrial membrane potential. Rotenone (a complex I
inhibitor) also induced a decrease of TMRM fluorescence, however PKAN cells responded
slower and to a reduced extent than control cells (Fig 3E). This suggested that either complex I
in PKAN neuronal cells was ineffective at generating a membrane potential or NADH sub-
strate availability from the TCA cycle was decreased.
Fig 2. Analysis of the coenzyme A biosynthetic pathway in control and mutant iPSC-derived neurons. A)
Analysis of the short chain CoA species by HPLC, with focused analysis on the simple CoA-SH and acetyl-CoA. B)
Comparison of pooled data for control and patient-derived neurons displaying comparable levels of short chain
acid-soluble CoAs. Patient 1 = 2 clones, patient 2 = 3 clones, patient 3 = 1 clone. C) Analysis of long chain CoA
species in the individual lines and D) pooled data, analysed by HPLC. Patient 1 = 1 clone, patient 2 = 2 clones,
patient 3 = 1 clone. E) UPLC-MS/MS analysis of uptake of stable isotope vitamin B5 from the media in control and
patient-derived neurons, measured as a ratio of total B5 relative to isotopically labelled B5.) Patient 1 = 1 clone,
patient 2 = 2 clones, patient 3 = 1 clone. Numbers in histograms represent experimental replicates.
https://doi.org/10.1371/journal.pone.0184104.g002
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To elucidate whether complex I was dysfunctional or starved of substrates, mitochondrial
NADH redox levels were measured (Fig 3F and 3G) and found to be significantly reduced in
PKAN neuronal cells under basal conditions (pooled controls: 60.1±9.5%, n = 24; versus
pooled patients: 24.3±10.6%, n = 36. p = 0.0139). The application of the mitochondrial uncou-
pler FCCP, to fully deplete NADH levels by stimulating mitochondrial respiration, and NaCN,
to block mitochondrial respiration and thus NADH consumption, enabled the rate of NADH
production and maximal pool of NADH in mitochondria to be estimated (Fig 3F–3H). A
trend towards a reduced total pool of NADH was evidenced in PKAN neuronal cells. Together
these observations were thus able to explain the reduction in complex I activity due to lack of
NADH substrate availability.
Similar analysis of the complex II substrate FAD revealed that PKAN neuronal cells dis-
played a significantly lower FAD redox index (pooled controls: 89.5±8.2%, n = 24; versus
pooled patients; 42.4±8.0%, n = 36. p = 0.0001) (Fig 3I–3K), indicating an inhibited rate of
Fig 3. Bioenergetic profile of PANK2-deficient patient-derived neurons. A) Analysis of mitochondrial
membrane potential using the fluorescent dye TMRM in stem cells and neurons from control and patient-
derived lines. Data from individual lines (Ai) and pooled data of controls versus patients (Aii) is presented. B)
Representative images of TMRM fluorescence (red) and calcein (to depict cell borders–green). C-D) Neurons
were pre-treated for 30 minutes with the iron chelator DFO prior to TMRM measurement. Pre-treatement led
to an increase in mitochondrial membrane potential in all lines. E) Representative traces of analyses into
electron transport chain function by sequential application of inhibitors to complex V (oligomycin), complex I
(rotenone) and the mitochondrial uncoupler (FCCP). Rotenone caused a partial depolarisation in patient cells,
demonstrating dysfunction of complex I. Oligomycin caused a substantial depolarization in both control and
patient-derived cells. F-H) Analysis of NADH autofluorescence to quantify the redox index of NAD+/NADH (Gi
individual lines and Gii pooled data) revealing reduced redox index in patient derived cells. H) Quantification of
the total NADH pool. I-K) Analysis of cellular FAD reveals a reduced redox index in patient-derived cells (Ji
and Jii) despite similar mitochondrial pools (K). Scale bar represents 10 μm or 20 μm as depicted. Significance
was calculated via student’s t test (C, H, K) and one way ANOVA with post-hoc Tukey’s HSD correction for
multiple comparisons (A, G, J) *p<0.05, **p<0.01, ***p<0.001, ns, not significant.
https://doi.org/10.1371/journal.pone.0184104.g003
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complex II dependent respiration. Altogether, these investigations provide evidence for a
defective electron transport chain in neurons carrying the PANK2 mutation.
Increased ROS production and oxidative stress in PKAN patient-derived
neuronal cells
Using the fluorescent dye monochlorobimane (MCB), levels of the reduced form of the antiox-
idant glutathione (GSH) were measured in control and patient-derived neuronal cells (Fig 4A
and 4B). Compared with controls cells, MCB fluorescence intensity was significantly decreased
in both undifferentiated patient-derived iPSCs (pooled controls: 512.3±73.5, n = 90; versus
pooled patients: 431.0±17.6, n = 127. p = 0.3022) and PKAN neuronal cells (pooled controls:
1151.0±36.6, n = 105; versus pooled patients: 675.6±21.7, n = 120. p<0.0001), representing
a decreased intracellular antioxidant pool. The lower reduced glutathione level in iPSCs com-
pared to neuronal cells (Fig 4B) is consistent with the low oxidative phosphorylation status
and ROS production of iPSCs that metabolically correspond to an early embryo [34].
ROS generation rates in the neuronal cells were measured by dihydroethidium oxidation as
a direct readout of superoxide (O2
-) production. Under basal conditions, O2
- generation was
consistently higher in PKAN neuronal cells compared with control cells (pooled controls: 41.7
±2.6, n = 46; versus pooled patients: 83.2±3.0, n = 54. p<0.0001) (Fig 4C and 4D). Lipid
peroxidation, assessed via the ratiometric dye BODIPY-C11, was also found to be significantly
higher in PKAN neuronal cells from two of the patients whereas cells derived from patient 2
showed a similar trend but did not reach significance (0.59683±0.06744, n = 196 for pooled
patients, compared to 0.26±0.022, n = 86 for pooled controls; p<0.0001 Fig 4E).
Following the findings in Fig 3C, the relationship with iron and PKAN neuron associated
oxidative damage was explored. Surprisingly, 30 minutes pre-treatment of neuronal cells with
DFO increased ROS generation in both control and patient-derived cells (pooled controls:
112.5±4.6; n = 46; versus pooled patients: 122.0±2.4; n = 53. p = 0.0782) (Fig 4D).
Taken together, these data provide evidence that the mitochondrial dysfunction observed
in patient-derived neuronal cells leads to increased ROS generation and downstream oxidative
damage. In our conditions, iron chelation exacerbated ROS generation and worsened the
PKAN neuronal phenotype.
Cellular response to iron in PKAN patient-derived neuronal cells
Iron accumulation is a progressive pathological characteristic of PKAN seen via MRI during
life [35], however, it is unclear whether this is a cause of neurodegeneration or a consequence.
Here, the iron response pathway was assessed in control and patient-derived neuronal cells.
Response of the cellular iron-handling pathway was analyzed in response to 18 hours iron
treatment (50 μM ferric ammonium citrate (FAC)) (Fig 5A). Across all cell lines and consistent
with a reduction in cellular iron import, TfR expression was reduced at the transcriptional and
expression levels (Fig 5B–5D). The cytosolic iron storage molecule Ferritin (FTH and FTL)
exhibited increased protein levels in all lines, consistent with its translational control by iron
response genes [36].
Interestingly, Ferroportin expression was significantly increased in patient-derived neuronal
cells versus controls, in basal conditions and in response to iron treatment (Fig 5B), suggesting
a cellular response for increased iron export. No significant transcriptional change in response
to iron was observed for MFRN1/2 or PANK2, however, a trend to increased FTMT expression
was witnessed in patient-derived cells, hinting to increased mitochondrial iron storage (Fig
5B). It is noteworthy that PANK2 expression is similar between control and patient-derived
neuronal cells, whereas protein levels are reduced in patient-derived cells (Fig 1E and 1F).
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Fig 4. PANK2 mutations result in increased rate of ROS production, depletion of cellular GSH and higher
oxidative stress. A) Representative images of glutathione levels in control and patient-derived neurons measured
by monochlorobimane (MCB) fluorescence in live cells. B) Quantification of MCB fluorescence in iPSCs and
neuronal cells showed reduced glutathione levels in patient-derived cells and lower levels in iPSCs, (Bii shows
pooled data). C) Basal rates of ROS production were quantified in neurons using the dihydroethidium assay. D)
Quantification showed an increased rate of ROS production in patient cells compared to controls and in all cell lines
in response to 30 minutes pre-incubation with iron chelator DFO (Dii depicts pooled data from Di). E) The level of lipid
peroxidation was quantified in the neuronal cells using the ratiometric dye BODIPY C11 and two of the patient-
derived neuronal cells displayed significantly higher levels of lipid peroxidation (pooled data shown in Eii). Scale bar
represents 20 μm. Significance was calculated via one way ANOVA with post-hoc Tukey’s HSD correction for
multiple comparisons *p<0.05, **p<0.01, ***p<0.001, ns not significant.
https://doi.org/10.1371/journal.pone.0184104.g004
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Fig 5. Neuronal response to excess extracellular iron treatment. A) Schematic representation of the iron handling
gene products analyzed in this figure. Transferrin receptor (TFR) binds Transferrin bound extracellular iron and is
internalised via endocytosis. Ferritin molecules FTH and FTL bind the cytosolic labile iron pool. Iron import to
mitochondria is performed by Mitoferrins (MFRN1 and MFRN2) and excess mitochondrial iron is stored in Mitochondrial
Ferritin (FTMT). Neuronal iron export is performed by Ferroportin (FPN). B) Quantitative PCR analysis of iron responsive
genes under basal conditions (dark grey bars) and after 18 hours of 50 μM ferric ammonium citrate treatment (light grey
bars). C) Western blot analysis of iron responsive proteins TFR and FTH. D) Densitometry analysis of the western blots
in C). Patient 1 = 2 clones, patient 2 = 2 clones, patient 3 = 2 clones. C-D) Patient 1 = 1 clone, patient 2 = 1 clone, patient
3 = 1 clone. *p<0.05, **p<0.01. Numbers in histograms represent experimental replicates, and n = 4 throughout B).
https://doi.org/10.1371/journal.pone.0184104.g005
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Total iron content is unchanged in patient-derived neuronal cultures
To investigate whether the small differences in expression of FTMT and FPN in response to
extracellular iron (Fig 5B) related to altered cellular iron content, absolute metal ion content
was measured by inductively coupled plasma mass spectrometry (ICP-MS). In all neuronal
lines, elevated intracellular iron content upon incubation with FAC (50 μM; 18 hours) was
confirmed and no change was observed between control and PKAN neuronal cells (Fig 6).
Data indicates a largely appropriate iron response from PKAN neuronal cells that preserves
intracellular levels of iron even in an elevated extracellular iron environment. An exception is
the consistent increase in FPN expression in patient-derived cells versus controls in both basal
conditions and under iron stress, which may indicate a compensatory measure to maintain
intracellular iron levels by enhancing iron export.
Discussion
In this study, PKAN patient-derived neuronal cells have been generated in an attempt to iden-
tify early mechanisms of neurodegeneration in NBIA. These cells represent a human model
Fig 6. Analysis of the neuronal iron content. Neuronal pellets were analyzed for total iron content by
ICP-MS in basal conditions and after 16 hours of FAC media supplementation. A) Individual data shown for
each biological replicate and B) shows mean results for control lines versus patient-derived neuronal pellets.
Control and patient-derived neurons displayed similar levels of basal iron content as well as similar storage of
excess iron after iron stress. Numbers in histograms represent experimental replicates.
https://doi.org/10.1371/journal.pone.0184104.g006
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with appropriate gene dosage of clinically proven pathogenic mutations in which to study the
earliest underlying consequences of PANK2 mutations in developmentally immature neuronal
cells.
Cortical neurons represent a relevant model of PKAN, as one of the cell types affected by
axonal swellings and gliosis, additional to the main site of pathology in the globus pallidus
[19]. There currently exists no stem cell differentiation protocol towards pallidal neurons and
the cortical differentiation protocol employed here is highly efficient and generates very
homogenous cortical cultures due to the default nature of this developmental paradigm [27]. It
should be noted that other cell types exist in the culture, for example glial cells and some pro-
genitor cells that persist, together representing less than 5% of cells [27]. These cells represent
a minority, however we cannot discount contributions of these cells to our data, for example
the provision of metabolites from astrocytes to neurons for oxidative phosphorylation.
We observed a significant degree of variability in cellular responses to many experimental
paradigms; including the fact that cells derived from patient 1 often responded similar to con-
trols. These variabilities may represent tissue culture artefact and a consequence of the cells
being cultured outside of their natural context and one example of this is the substantial
change in transcription witnessed in primary microglia just six hours after being placed in cul-
ture [37].
Our observation that the relative proportion of free CoA to acetyl-CoA changes through
differentiation suggests a metabolic alteration between the stem cells and neurons. This finding
calls for future investigations to describe the metabolic states of the two cell types and changes
through neuronal differentiation.
We find that point mutations associated with atypical PKAN lead to unaltered PANK2
expression in neuronal cultures but a reduction in PANK2 protein levels. Hypothetically, this
could be explained via alterations in folding and degradation of the putative unfolded protein;
further investigation is required. These findings are in line with iPSC-derived neurons har-
bouring premature stop codons; showing unaltered PANK2 transcription but a total lack of
protein [17]. It is noteworthy that biochemically, a number of peptides harbouring PANK2
mutations display normal enzyme function [32]. Thus protein dosage may be central to the
disease mechanism, with juvenile onset displaying no PANK2 protein and atypical PKAN a
reduced level.
The data presented here demonstrates that pathogenic point mutations in PANK2 do not
alter neuronal CoA levels or the metabolic flux of pantothenate. This suggests that there is
either a distinct cellular function for mitochondrial PANK2 or that cytosolic PANK enzymes
may be compensating for a PANK2 deficiency. The ability of mitochondrial human PANK2
and only mitochondrial isoforms of drosophila Pank to rescue phenotypes in Drosophila Pank
knockouts [13], supports the former concept, whereas the ability of human PANK3 and
PANK4 to partially rescue knockout flies supports the latter. Alternatively, CoA flux might
respond in a faulty manner in relation to stress in the setting of the ageing or diseased brain.
Dysfunctional mitochondrial oxidative phosphorylation may be a key component in the
PKAN brain and altered mitochondrial membrane potential has been seen in other PKAN
models. Reduced mitochondrial membrane potential and defective ATP production has been
described in PANK2 knockout mouse models, patient-derived fibroblasts as wells as induced
neuronal models [7,16]. The increased membrane potential seen in this study may represent a
compensatory response of the cells to mitochondrial deficits, in the context of atypical disease
mutations. Mitochondrial and metabolic deficiencies could explain the adult onset of neurode-
generation through altered environmental stresses and diet in this highly energy demanding
cell type. This is reinforced by mutations in PANK1 being linked with hyperglycaemia [38,39].
We report a metabolically immature neuronal phenotype in PANK2 mutants as well as in
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control lines, as seen by depolarization of mitochondria in response to oligomycin application
after 100 days of differentiation. This result highlights that all cultures analysed in this study
are partially glycolytic, contrary to mature primary neurons in culture. Due to this observation,
some metabolic consequences of PANK2 mutations may be masked by the fact that our cul-
tures are not entirely dependent on mitochondrial oxidative phosphorylation.
Closer analysis of the mitochondrial physiology demonstrated that the cells were defective
in complex I of the electron transport chain. Our data indicate that a lack of NADH substrate
provided by the TCA cycle may be central to this deficiency. In addition to NADH, PANK2
mutations reduce the amount of FADH production in complex II. This observation is rein-
forced by changes in NADH in tissue homogenate in Pank1/Pank2 double knockout mice [11]
and validates the hypotheses gleaned in studies in iPSC-derived neurons [17]. Importantly,
irrespective of PANK2 mutations, our cultures rely on glycolysis to compensate for inefficient
oxidative phosphorylation and for increased ATP consumption by the ATPase to maintain the
mitochondrial membrane potential. It is interesting that undifferentiated iPSCs display some
mitochondrial abnormalities in addition to neuronal cells, namely increased TMRM fluores-
cence and reduced antioxidant levels. Levels of antioxidants have been shown to be altered in
PKAN patient-derived fibroblasts and transdifferentiated neurons, including lower levels of
reduced glutathione [15,16]. However, in the brain an increase in levels of glutathione-cysteine
have been described, suggesting increased oxidised glutathione and potentially oxidative stress
[40]. These consistencies again suggest a selective vulnerability of certain neurons to a consis-
tent mutation-associated phenotype.
The reported ultrastructural disruption of cristae organization and mitochondrial swelling
in a PKAN transgenic model [14] and in iPSC-derived neurons [17] could occur as a cause or
result of the metabolic dysfunction described here. This physical disruption of the respiratory
chain could lead to electron leakage and could be another reason for the reversal of the ATP
synthase to maintain mitochondrial membrane potential described here. ROS is a normal cel-
lular signal for multiple physiological processes; however prolonged exposure to high levels
combined with environmental stresses will inevitably lead to damaged cellular components.
Increased ROS generation and subsequent lipid peroxidation as a result of altered oxidative
phosphorylation in PKAN neurons could potentially explain the post-developmental onset of
the NBIA.
Of note, is the finding that iron chelation increases mitochondrial membrane potential and
ROS generation in both control and mutant cells. This can be explained as DFO is a specific Fe
(III) chelator, altering the equilibrium between the two redox states. In turn, DFO thus favours
the oxidation of Fe(II) to Fe(III), leading to the release of electrons and the formation of ROS.
This is an important finding with respect to the relevance of iron to mitochondrial homeosta-
sis, however, it is important to consider that we do not see iron accumulation in our model.
For this reason, we cannot comment on the effectiveness of iron chelation with respect to
ongoing clinical trials in PKAN using the cell permeable iron chelator deferiprone [4]. Current
findings calls for further investigations in other model systems that display iron accumulation
and elucidating the role of iron in healthy mitochondria.
Iron deposition is a characteristic feature of NBIAs such as PKAN and is increasingly
apparent as an early pathological feature in other neurodegenerative diseases such as AD and
PD [41]. It is still unclear whether defective iron homeostasis is a cause or consequence of the
neuropathological events in these diseases, but brain imaging has identified that its accumula-
tion is clearly progressive during life [42] and may occur prior to symptom onset [43]. The
homeostatic response of iron regulatory proteins and total intracellular iron levels appear
largely normal in patient-derived neuronal cells under these conditions. However, altered FPN
expression reported here and in PANK2 knockout cell lines [44] suggest an increase in the iron
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export pathway may exist. A trend to increased MTFT expression in PANK2 mutant neuronal
cultures not only reinforces a mitochondrial defect, but also may indicate a further attempt by
the cell to sequester excess iron safely. It is tempting to speculate that a mitochondrial defect
could lead to altered iron storage in the mitochondrial matrix and increased iron export via
FPN, leading to iron dyshomeostasis and a potential accumulation over time. Thus, mitochon-
drial phenotypes may theoretically precede iron accumulation and underlie PKAN disease
progression.
Orellana et. al. performed investigations into PKAN in cortical neurons derived from
iPSCs. This study focused on early onset-associated mutations that lead to a lack of mature
PANK2 protein. The authors also see mitochondrial abnormalities and increased ROS produc-
tion in iPSC-derived cortical neuronal cultures, albeit it with reduced mitochondrial mem-
brane potential. This may hint to different compensatory mechanisms between early-onset
and late-onset-associated mutations in PANK2 [17]. The authors also hypothesise altered
NADH supply to the mitochondria; here we have shown this link to be valid via reduced
NADH redox ratios. Orellana et al elegantly show that the wild-type PANK2 transgene can
reverse the disease phenotypes, but also put forward extracellular CoA supplementation as a
novel therapeutic avenue [17,45]. This strategy has also been shown to reverse disease pheno-
types in model organisms of CoA imbalance, as developmental, vasculature and metabolic
deficiencies from Coasy and Pank2 knockdown zebrafish are also reversed via CoA supple-
mentation [46,47].
In conclusion, the generation and characterisation of PKAN patient-derived iPSC neuronal
cells has provided new insights into the underlying mechanisms of NBIA with relevance to
other diseases exhibiting iron accumulation. Reduced cofactor supply for oxidative phosphor-
ylation can explain the mitochondrial defects in patient-derived neuronal cultures, which in
turn precedes iron accumulation. Additionally, the effects of iron chelation described here call
for careful consideration in the future therapeutic strategies.
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S1 Fig. Characterisation of patient-derived iPSC lines. Karyographs to show karyotype sta-
bility in the patient-derived reprogrammed iPSCs. All patient-derived iPSCs displayed normal
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derived neurons (at least 100 days), mutations depicted within red boxes. gDNA–genomic
DNA.
(TIFF)
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